Search Results - "Ng, Siobhan"

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer by Beer, Tomasz M, Kwon, Eugene D, Drake, Charles G, Fizazi, Karim, Logothetis, Christopher, Gravis, Gwenaelle, Ganju, Vinod, Polikoff, Jonathan, Saad, Fred, Humanski, Piotr, Piulats, Josep M, Gonzalez Mella, Pablo, Ng, Siobhan S, Jaeger, Dirk, Parnis, Francis X, Franke, Fabio A, Puente, Javier, Carvajal, Roman, Sengeløv, Lisa, McHenry, M Brent, Varma, Arvind, van den Eertwegh, Alfonsus J, Gerritsen, Winald

“…Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic…”
Get full text

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial by Kwon, Eugene D, Prof, Drake, Charles G, MD, Scher, Howard I, Prof, Fizazi, Karim, Prof, Bossi, Alberto, MD, van den Eertwegh, Alfons J M, MD, Krainer, Michael, MD, Houede, Nadine, MD, Santos, Ricardo, MD, Mahammedi, Hakim, MD, Ng, Siobhan, MD, Maio, Michele, MD, Franke, Fabio A, MD, Sundar, Santhanam, MBBS, Agarwal, Neeraj, MD, Bergman, Andries M, MD, Ciuleanu, Tudor E, Prof, Korbenfeld, Ernesto, MD, Sengeløv, Lisa, MD, Hansen, Steinbjorn, MD, Logothetis, Christopher, Prof, Beer, Tomasz M, Prof, McHenry, M Brent, PhD, Gagnier, Paul, MD, Liu, David, MD, Gerritsen, Winald R, Prof

“…Summary Background Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. Our aim was to…”
Get full text

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors by Fizazi, Karim, Drake, Charles G., Beer, Tomasz M., Kwon, Eugene D., Scher, Howard I., Gerritsen, Winald R., Bossi, Alberto, den Eertwegh, Alfons J.M. van, Krainer, Michael, Houede, Nadine, Santos, Ricardo, Mahammedi, Hakim, Ng, Siobhan, Danielli, Riccardo, Franke, Fabio A., Sundar, Santhanam, Agarwal, Neeraj, Bergman, André M., Ciuleanu, Tudor E., Korbenfeld, Ernesto, Sengeløv, Lisa, Hansen, Steinbjorn, McHenry, M. Brent, Chen, Allen, Logothetis, Christopher

“…The phase 3 trial CA184-043 evaluated radiotherapy to bone metastases followed by Ipilimumab or placebo in men with metastatic castrate-resistant prostate…”
Get full text

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial by Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Y, McJannett, Margaret M, Stockler, Martin R, Violet, John A, Williams, Scott G, Martin, Andrew J, Davis, Ian D, Azad, Arun A, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Ng, Siobhan, Pattison, David A, Ramdave, Shakher, Rana, Nisha, Redfern, Andrew D, Rutherford, Natalie K, Sandhu, Shahneen, Scott, Andrew M, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Violet, John A, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, Zhang, Alison Y

“…Lutetium-177 [177Lu]Lu-PSMA-617 is a radiolabelled small molecule that delivers β radiation to cells expressing prostate-specific membrane antigen (PSMA), with…”
Get full text

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer by Gulley, James L, Borre, Michael, Vogelzang, Nicholas J, Ng, Siobhan, Agarwal, Neeraj, Parker, Chris C, Pook, David W, Rathenborg, Per, Flaig, Thomas W, Carles, Joan, Saad, Fred, Shore, Neal D, Chen, Liddy, Heery, Christopher R, Gerritsen, Winald R, Priou, Frank, Langkilde, Niels C, Novikov, Andrey, Kantoff, Philip W

“…PROSTVAC, a viral vector-based immunotherapy, prolonged median overall survival (OS) by 8.5 months versus placebo in metastatic castration-resistant prostate…”
Get full text

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer by Chi, Kim N, Rathkopf, Dana, Smith, Matthew R, Efstathiou, Eleni, Attard, Gerhardt, Olmos, David, Lee, Ji Youl, Small, Eric J, Pereira de Santana Gomes, Andrea J, Roubaud, Guilhem, Saad, Marniza, Zurawski, Bogdan, Sakalo, Valerii, Mason, Gary E, Francis, Peter, Wang, George, Wu, Daphne, Diorio, Brooke, Lopez-Gitlitz, Angela, Sandhu, Shahneen

“…Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR)…”
Get full text

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial by Buteau, James P, Martin, Andrew J, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen, Joshua, Anthony M, Francis, Roslyn J, Zhang, Alison Y, Scott, Andrew M, Lee, Sze-Ting, Azad, Arun A, McJannett, Margaret M, Stockler, Martin R, Williams, Scott G, Davis, Ian D, Hofman, Michael S, Akhurst, Tim, Alipour, Ramin, Azad, Arun A, Banks, Patricia, Beaulieu, Alexis, Buteau, James P, Chua, Wei, Davis, Ian D, Dhiantravan, Nattakorn, Emmett, Louise, Ford, Kate, Hofman, Michael S, Francis, Roslyn J, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J, Hsiao, Edward, Iravani, Amir, Joshua, Anthony M, Kirkwood, Ian D, Kong, Grace, Kwan, Edmond M, Langford, Ailsa, Lawrence, Nicola, Lee, Sze-Ting, Lewin, Jeremy, Lin, Peter, Martin, Andrew J, McDonald, William, McJannett, Margaret M, Moodie, Kate, Murphy, Declan G, Ng, Siobhan, Pattison, David A, Pokorski, Izabella, Ramdave, Shakher, Ravi Kumar, Aravind S, Redfern, Andrew D, Rutherford, Natalie K, Saghebi, Javad, Sandhu, Shahneen, Scott, Andrew M, Spain, Lavinia, Stockler, Martin R, Subramaniam, Shalini, Tan, Thean Hsiang, Thang, Sue Ping, Tran, Ben, Wallace, Roslyn, Weickhardt, Andrew, Williams, Scott G, Yip, Sonia, Zhang, Alison Y

“…Previously, results from the TheraP trial showed that treatment with lutetium-177 [177Lu]Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA)…”
Get full text

A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer by GUNAWARDANA, Dishan H, BASSER, Russell L, AMOR, Pene, CRUMP, David, NG, Siobhan, NATION, Roger L, BEGLEY, C. Glenn, DAVIS, Ian D, CEBON, Jonathan, MITCHELL, Paul, UNDERHILL, Craig, KILPATRICK, Trevor J, REARDON, Katrina, GREEN, Michael D, BARDY, Peter

“…Purpose: Leukemia inhibitory factor (LIF) is a pleiotropic molecule of the interleukin 6 family of cytokines. We aimed to examine the safety, pharmacokinetics,…”
Get full text

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy by Ryan, Charles J, Smith, Matthew R, de Bono, Johann S, Molina, Arturo, Logothetis, Christopher J, de Souza, Paul, Fizazi, Karim, Mainwaring, Paul, Piulats, Josep M, Ng, Siobhan, Carles, Joan, Mulders, Peter F.A, Basch, Ethan, Small, Eric J, Saad, Fred, Schrijvers, Dirk, Van Poppel, Hendrik, Mukherjee, Som D, Suttmann, Henrik, Gerritsen, Winald R, Flaig, Thomas W, George, Daniel J, Yu, Evan Y, Efstathiou, Eleni, Pantuck, Allan, Winquist, Eric, Higano, Celestia S, Taplin, Mary-Ellen, Park, Youn, Kheoh, Thian, Griffin, Thomas, Scher, Howard I, Rathkopf, Dana E

“…Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant…”
Get full text

Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer by Sternberg, Cora, Armstrong, Andrew, Pili, Roberto, Ng, Siobhan, Huddart, Robert, Agarwal, Neeraj, Khvorostenko, Denis, Lyulko, Olexiy, Brize, Arija, Vogelzang, Nicholas, Delva, Rémy, Harza, Mihai, Thanos, Anastasios, James, Nicholas, Werbrouck, Patrick, Bögemann, Martin, Hutson, Thomas, Milecki, Piotr, Chowdhury, Simon, Gallardo, Enrique, Schwartsmann, Gilberto, Pouget, Jean-Christophe, Baton, Frédérique, Nederman, Thore, Tuvesson, Helen, Carducci, Michael

“…Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival (PFS) in a randomized,…”
Get full text

Overall survival with [ 177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial by Hofman, Michael S, Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P, Joshua, Anthony M, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Ng, Siobhan, Francis, Roslyn J, Gedye, Craig, Rutherford, Natalie K, Weickhardt, Andrew, Scott, Andrew M, Lee, Sze-Ting, Kwan, Edmond M, Azad, Arun A, Ramdave, Shakher, Redfern, Andrew D, Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R, Williams, Scott G, Martin, Andrew J, Davis, Ian D

“…The TheraP study reported improved prostate-specific antigen responses with lutetium-177 [ Lu]Lu-PSMA-617 versus cabazitaxel in men with metastatic…”
Get full text

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial by Petrylak, Daniel P, de Wit, Ronald, Chi, Kim N, Drakaki, Alexandra, Sternberg, Cora N, Nishiyama, Hiroyuki, Castellano, Daniel, Hussain, Syed A, Fléchon, Aude, van der Heijden, Michiel S, Matsubara, Nobuaki, Necchi, Andrea, Géczi, Lajos, Ou, Yen-Chuan, Coskun, Hasan Senol, Su, Wen-Pin, Percent, Ivor J, Lee, Jae-Lyun, Laestadius, Fredrik, Peer, Avivit, Garcia del Muro, Xavier, Cicin, Irfan, Vaishampayan, Ulka, Aragon-Ching, Jeanny B, Hamid, Oday, Wijayawardana, Sameera, Russo, Francesca, Zimmermann, Annamaria H, Bell-McGuinn, Katherine M, Wong, Suet-Lai Shirley, Tan, Thean Hsiang, Hovey, Elizabeth Jane, Clay, Timothy Dudley, Wan Ng, Siobhan Su, Rutten, Annemie, Dumez, Herlinde, Ferrario, Cristiano, Sengeloev, Lisa, Jensen, Niels Viggo, Thibault, Constance, Laguerre, Brigitte, Joly, Florence, Culine, Stéphane, Becht, Catherine, Niegisch, Günter, Stöckle, Michael, Grimm, Marc-Oliver, Schultze-Seemann, Wolfgang, Kalofonos, Haralambos, Mavroudis, Dimitrios, Karavasilis, Vasilis, Révész, Janos, Leibowitz-Amit, Raya, Kejzman, Daniel, Sarid, David, Massari, Francesco, Osawa, Takahiro, Miyajima, Naoto, Shinohara, Nobuo, Fukuta, Fumimasa, Ohyama, Chikara, Obara, Wataru, Yamashita, Shinichi, Tomita, Yoshihiko, Kawai, Koji, Oyama, Masafumi, Yonese, Junji, Uemura, Motohide, Tsunemori, Hiroyuki, Yokomizo, Akira, Nagamori, Satoshi, Lee, Hyo Jin, Park, Se Hoon, Rha, Sun Young, Kim, Yu Jung, Lee, Yun-Gyoo, Vazquez Cortés, Leticia, Lorena Urzua Flores, Claudia, Blaisse, Reinoud J.B., Aarts, Maureen J.B., Schenker, Michael, Herzal, Alina Amalia, Udrea, Anghel Adrian, Karlov, Petr, Fomkin, Roman, Grande, Enrique, Lin, Chia-Chi, Yeh, Su-Peng, Erman, Mustafa, Urun, Yuksel, Golovko, Yuriy, Sinielnikov, Ivan, Crabb, Simon J., Syndikus, Isabel, Sundar, Santhanam, Pan, Chong Xian, Schwarz, James K., Acs, Peter Istvan, Hainsworth, John D., Lawler, William Eyre

“…Ramucirumab—an IgG1 vascular endothelial growth factor receptor 2 antagonist—plus docetaxel was previously reported to improve progression-free survival in…”
Get full text

Sequential 177LuLu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study by Azad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S

“…Lutetium-177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 improves survival and quality of life in patients with metastatic castration-resistant…”
Get full text

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial by Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, Yip, Sonia, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S, McJannett, Margaret, Martin, Andrew James, Stockler, Martin R, Davis, Ian D

“…Enzalutamide and lutetium-177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic…”
Get full text

Changing Management and Survival in Patients With Stage IV Colorectal Cancer by Platell, Cameron, Ng, Siobhan, OʼBichere, Austin, Tebbutt, Niall

“…BACKGROUND:Patients with metastatic colorectal cancers have poor outcomes. Yet recent developments in the use of chemotherapy and surgery have promised…”
Get full text

177LuLu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial by Emmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M, Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J, Goh, Jeffrey C, Pattison, David A, Tan, Thean Hsiang, Kirkwood, Ian D, Gedye, Craig, Rutherford, Natalie K, Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P, Voskoboynik, Mark, Redfern, Andrew D, Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia, Butler, Patrick, Zhang, Alison Yan, Yip, Sonia, Thomas, Hayley, Langford, Ailsa, Hofman, Michael S, McJannett, Margaret, Martin, Andrew James, Stockler, Martin R, Davis, Ian D

“…Enzalutamide and lutetium-177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic…”
Get full text

A practical guide for the use of apalutamide for non‐metastatic castration‐resistant prostate cancer in Australia by Marx, Gavin, Chowdhury, Simon, Krieger, Laurence, Hovey, Elizabeth, Shapiro, Jeremy, Tran, Ben, Tan, Thean Hsiang, Ng, Siobhan, Woo, Henry H.

“…Studies of patients with castrate‐resistant prostate cancer at high risk of developing overt metastases but with no current evidence of evaluable disease on…”
Get full text

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901) by Emmett, Louise, Subramaniam, Shalini, Martin, Andrew James, Zhang, Alison Yan, Yip, Sonia, Crumbaker, Megan, Rana, Nisha, Francis, Roslyn J., Hofman, Michael S, Joshua, Anthony M., Sandhu, Shahneen Kaur, Azad, Arun, Gedye, Craig, Weickhardt, Andrew James, Goh, Jeffrey C., Ng, Siobhan, Voskoboynik, Mark, McJannett, Margaret Mary, Stockler, Martin R., Davis, Ian D.

“…Abstract only TPS205 Background: 177 Lu‐PSMA‐617 (LuPSMA) is a novel radionuclide with promising activity and tolerability in metastatic castration-resistant…”
Get full text

Cabazitaxel in patients with metastatic castration‐resistant prostate cancer: safety and quality of life data from the Australian early access program by Parente, Phillip, Ng, Siobhan, Parnis, Francis, Guminski, Alex, Gurney, Howard

“…Aim Cabazitaxel is a next generation taxane that has been shown to improve overall survival in patients with metastatic castration‐resistant prostate cancer…”
Get full text

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study by Azad, Arun A, Bressel, Mathias, Tan, Hsiang, Voskoboynik, Mark, Suder, Aneta, Weickhardt, Andrew J, Guminski, Alexander, Francis, Roslyn J, Saghebi, Javad, Dhiantravan, Nattakorn, Joshua, Anthony M, Emmett, Louise, Horvath, Lisa, Murphy, Declan G, Hsiao, Edward, Balakrishnar, Bavanthi, Lin, Peter, Redfern, Andrew, Macdonald, William, Ng, Siobhan, Lee, Sze-Ting, Pattison, David A, Nadebaum, David, Kirkwood, Ian D, Hofman, Michael S, Akhurst, T, Alipour, R, Au, L, Banks, P, Emerson, B, Hussain, N, Haskali, M, Lewin, J, Linklater, R, Kostos, L, Kashyap, R, Krishanth, P, Kong, G, Kumar, A, Murphy, D, Roselt, P, Sandhu, S, Scalzo, M, Tran, B, Wallace, R, Spain, L, Bourke, H, Milton, A, Russo, D, Bills, M, Chew, C, Hsieh, W, Crouch, B, Smyth, D, Pandelus, S, Lam, H, Gan, C, Goh, J, Scott, A, Hafeez, U, Ackermann, U, Young, K, Poon, A, Pathmaraj, K, Schembri, G, Roach, P, Bailey, D, Hung, T, Asad, A, Hagan, T, Watts, J, Campbell, E, Chua, W, Pal, A, Crumbaker, M, Nguyen, A, Yam, A, Chen, J, Ardolino, L, Kongrak, K, Ratnayake, L

“…Lutetium-177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 improves survival and quality of life in patients with metastatic castration-resistant…”
Get full text